VIP Gloves Limited (ASX:VIP) Reports Quarterly Update
VIP Gloves Limited (ASX:VIP) announces operational updates, cash flow insights, and future manufacturing plans in its quarterly report for September 2024.
Tag: Shareholder Updates
VIP Gloves Limited (ASX:VIP) Reports December 2024 Quarterly Update
VIP Gloves Limited reports its December 2024 quarterly update, highlighting operational activities and plans for recommencing glove manufacturing.
Mirrabooka Investments Limited (ASX:MIR) Reports Strong Half-Year Results
Mirrabooka Investments Limited reports strong half-year results with an interim dividend increase and significant portfolio outperformance.
Visioneering Technologies (ASX:VTI) Announces Positive Interim Data
Visioneering Technologies (ASX:VTI) reports positive interim findings from the PROTECT trial on their NaturalVue® Multifocal 1 Day contact lenses.
Northern Minerals (ASX: NTU) Reports Significant Mineral Resource Increase
Northern Minerals (ASX: NTU) reports a 15% increase in the Mineral Resource Estimate for its Wolverine deposit at Browns Range.
Green Critical Minerals Ltd (ASX:GCM) Achieves Major Pilot Plant Milestone
Green Critical Minerals Ltd reports successful commissioning of its VHD Technology pilot plant, yielding high-density samples that exceed industry benchmarks.
Lachlan Star Limited (ASX:LSA) Confirms High-Grade Copper Intercepts at Basin Creek
Lachlan Star Limited confirms significant high-grade copper intercepts from its Basin Creek drilling program.
Resolution Minerals Ltd (ASX:RML) Quarterly Activities Report
Resolution Minerals Ltd (ASX:RML) releases its quarterly activities report, highlighting exploration updates and financial performance.
Bell Financial Group Ltd (ASX:BFG) Reports Significant Profit Growth
Bell Financial Group Ltd (ASX:BFG) announces a 26% increase in profit after tax, reaching $30.7 million for the full year.
Dimerix Limited (ASX:DXB) Marks Milestone with First Paediatric Patient in ACTION3 Trial
Dimerix Limited (ASX:DXB) has recruited its first paediatric patient for the ACTION3 Phase 3 clinical trial, targeting FSGS in children.